MedTrace Logo

Treatment of Atypical Resistant Facial Pain

NCT07250984 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2025-12-22

No results posted yet for this study

Summary

Facial pain in the trigeminal nerve region, which is not a migraine headache is often very persistent and difficult to treat. Research findings suggest that, similar to the mechanisms of migraine headache, the increased concentration of calcitonin gene-related peptide (CGRP) plays an important role in the mechanisms of facial pain.

Therefore, the hypothesis is that intravenous administration of ACMP will similarly disrupt central sensitization in facial pain as it does in migraine headaches.

Conditions

  • Facial Pain

Interventions

DRUG

intravenous administration of ACMP

30-minute infusion of 100 mg of eptinezumab, repeated after three months

Sponsors & Collaborators

  • Alenka Spindler-Vesel

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-03
Primary Completion
2026-11-03
Completion
2026-12-03

Countries

  • Slovenia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07250984 on ClinicalTrials.gov